therapy related myeloid neoplasm


Expand All | Collapse All

  • Entities

    • t-AML
    • t-MDS
    • t-MDS/MPN

  • Clinical

    • alkylating agent or radiation: 5-10 years onset, presents with MDS
    • topo II inhibitor: 1-5 years onset, presents with overt acute leukemia, translocations (MLL, RUNX1), can also have ALL t(4;11)

  • Morphology

    • Anemia, basophilia
    • blood: RBCs (macrocytosis, poikilocytosis), neutrophils (hypolobation, hypogranulation)
    • marrow: dysgranulopoiesis, dyserythropoiesis, ring sideroblasts
    		•